CompletedNCT03339778

The Benefit of 5% IVIG for Patients With Primary Immunodeficiency Disorders Who Experience Adverse Events on 10% IVIG Preparations

Studying Primary immunodeficiency

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
IMMUNOe Research Centers
Principal Investigator
Isaac Melamed, MD
IMMUNOe Research Centers
Enrollment
15 enrolled
Eligibility
10-75 years · All sexes
Timeline
20152017

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03339778 on ClinicalTrials.gov

Other trials for Primary immunodeficiency

Additional recruiting or active studies for the same condition.

See all trials for Primary immunodeficiency

← Back to all trials